Resistance to antiretroviral drugs remains an important limitation to successful human
immunodeficiency virus type 1 (HIV-1) therapy. Resistance testing can improve treatment …

Following large-scale roll-out of antiretroviral therapy in sub-Saharan Africa, the non-clinical
efficacy of antiretroviral therapy has received little attention. We aimed to systematically …

Background: Over 150 000 Malawians have started antiretroviral therapy (ART), in which
first-line therapy is stavudine/lamivudine/nevirapine. We evaluated drug resistance patterns …

Background. Episodes of viremia are common in African antiretroviral therapy (ART)
programs. We sought to describe viremia, resuppression, and accumulation of resistance …

Objective: Antiretroviral (ARV) therapies fail when behavioral or biologic factors lead to
inadequate medication exposure. The currently available methods to assess ARV exposure …

Objectives To evaluate the virological response and to describe the resistance profiles in the
case of failure after 6 months of first-line highly active antiretroviral therapy (HAART) in HIV-1 …

Objectives We describe the outcomes of second-line drug resistance profiles and predict the
efficacy of drugs for third-line therapy in patients monitored without the benefit of plasma HIV …

Introduction Access to antiretroviral treatment (ART) becomes more and more effective in
resource‐limited settings (RLS). However, this global effort would be even more profitable if …

The rate of virological failure was assessed in 386 adult patients attending the Centre
National Hospitalier Universitaire of Bangui, the capital city of the Central African Republic …

Objectives In resource-limited settings, few data are available on virological failure after long-
term first-line antiretroviral therapy. This study characterized the genotypic resistance …